A New Era in MASH: How Disease-Specific Therapies Are Changing the Gameand Best Practices for Clinical Integration

Society: DDW

Mitigating disease progression in MASH has been challenging due to a lack of disease-specific therapies. With FDA approval of the first MASH-specific therapy, and several other agents in advanced stages of development comes, a new era of disease management. This activity will explore the mechanism of action and efficacy of these novel therapies, including thyroid hormone receptor-? (THR-?) agonists, along with data on late-stage investigational therapies. Experts will also focus on case-based scenarios that discuss considerations for disease staging and assessment through non-invasive tests to ensure pharmacological management is tailored to the individual needs of each patient. This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. This activity is supported by an educational grant from Madrigal Pharmaceuticals.